论文部分内容阅读
目的观察华蟾素联合CHOP方案治疗非霍奇金淋巴瘤的疗效及毒性。方法 48例非霍奇金淋巴瘤患者随机分为华蟾素联合CHOP方案组(A组)和CHOP方案组(B组),A组:24例患者接受环磷酰胺750mg.m2,静脉注射,第1d;阿霉素50mg/m2,静脉注射,第1d;长春新碱1.4mg/m2,静脉注射,第1d;强的松100mg/d2,口服,第1~5d;华蟾素20ml,加入5%葡萄糖250ml内静脉滴注,第1~14d。B组24例患者接受CHOP方案化疗同A组,不应用华蟾素,两组均为21d为1周期,化疗4个周期。结果 A组:CR 10例(41.7%),PR 12例(50.0%),SD 1例(4.2%),PD1例(4.2%),有效率91.7%,疾病控制率为95.8%;B组:CR11例(45.8%),PR 4例(16.7%),SD6例(25.0%),PD 3例(12.5%),有效率62.5%,疾病控制率为87.5%。结论华蟾素联合CHOP方案治疗非霍奇金恶性淋巴瘤疗效较好,不良反应轻,患者可耐受。
Objective To observe the efficacy and toxicity of cinobufacini combined with CHOP regimen in the treatment of non-Hodgkin’s lymphoma. Methods Forty-eight patients with non-Hodgkin’s lymphoma were randomly divided into two groups: Cinobufacini combined with CHOP group (group A) and CHOP group (group B). Group A: 24 patients received cyclophosphamide 750mg.m2 intravenously, 1d; doxorubicin 50mg / m2, intravenous injection, the first day; vincristine 1.4mg / m2, intravenous injection, 1st day; prednisone 100mg / d2, orally, 1 ~ 5d; 5% glucose 250ml intravenous drip, the first ~ 14d. Twenty-four patients in group B received CHOP regimen with group A and no cinobufotalin. Both groups were given 21 cycles of 1 cycle and 4 cycles of chemotherapy. Results Group A had 10 cases (41.7%) of CR, 12 cases of PR (50.0%), 1 case of SD (4.2%) and 1 case of PD (91.7%) with disease control rate of 95.8% CR 11 cases (45.8%), PR 4 cases (16.7%), SD 6 cases (25.0%), and PD 3 cases (12.5%) with an effective rate of 62.5% and a disease control rate of 87.5%. Conclusion Cinobufacini combined with CHOP regimen is effective in treating non-Hodgkin’s lymphoma with mild side effects and tolerable in patients.